---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-203993"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-14T23:58:50.425695+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ORIC Q1 2026: rinzimetostat RP3D for Phase 3; $419.7M cash; enozertinib data due 2H 2026

## Summary
- Rinzimetostat 400 mg QD + darolutamide data showed landmark rPFS 93%/84%/84% at 3/4/5 months; no Grade 4/5 TRAEs.
- Cash and investments $419.7M as of March 31, 2026, including $59.9M from ATM. Expected runway into 2H 2028.
- Enrolled Phase 1b enozertinib monotherapy in 1L EGFR exon20 insertion NSCLC; data expected 2H 2026.
- R&D expenses $31.4M in Q1 2026 vs $24.6M in Q1 2025, driven by rinzimetostat and enozertinib advancement.

## SEC filing metadata
- accession: 0001193125-26-203993
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000119312526203993/0001193125-26-203993-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000119312526203993/oric-20260504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-203993
- JSON: https://secwatch.observer/filing/0001193125-26-203993.json
- Plain text: https://secwatch.observer/filing/0001193125-26-203993.txt

## Key facts
- Earnings Releases
  Oric Pharmaceuticals, Inc. reported financial results for the quarter ended March 31, 2026.
  - Period: the quarter ended March 31, 2026
  - Result: reported results
  source text: ORIC Pharmaceuticals, Inc. (the “Company”), issued a press release announcing its financial results for the fiscal quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1796280/000119312526203993/0001193125-26-203993-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.